Cipryl 20 WSP

Applications: Respiratory tract infection, Gastrointestinal infection, Urinary tract infection, Uterine Infection, Bone Infection, Ear Infection, Skin and Soft Tissue infection, Colibacillosis, salmonellosis, Infectious coryza, Mycoplasmosis (CRD), Fowl Cholera, Streptococcosis, Staphylococcosis
-----

Poultry: Colibacillosis, Salmonellosis, Infectious coryza, Mycoplasmosis (CRD), Fowl Cholera, Streptococcosis, Staphylococcosis. 

Prevention of secondary bacterial infection from Newcastle Disease, Infectious Bursal Disease etc.

Ciprofloxacin should be considered contraindicated in small and medium breed dogs from 2–8 months of age.

Hypersensitivity. Relatively contraindicated for young, growing animals due to cartilage abnormalities

Fluoroquinolone antibiotic.

Ciprofloxacin is a bactericidal and a concentration dependent agent, with susceptible bacteria cell death occurring within 20–30 minutes of exposure. Ciprofloxacin has demonstrated a significant post-antibiotic effect for both
786 gram-negative and gram-positive bacteria and is active in both stationary and growth phases of bacterial replication. Its mechanism of action is not thoroughly understood, but it is believed to act by inhibiting bacterial DNAgyrase (a type-II topoisomerase), thereby preventing DNA supercoiling and DNA synthesis.

Pharmacokinetics: ciprofloxacin are well absorbed after oral administration in most species. The pharmacokinetics of ciprofloxacin has been studied in dogs, calves, horses, and pigs. Oral bioavailability is approximately 50% in calves and 40% (only one pig studied) in pigs and it has an elimination half-life of about 2.5 hours in both species. Protein binding was significantly different for each species, with calves having about 70% of the drug bound and pigs only about 23% bound to plasma proteins. Elimination half-life is reported to be about 2.5 hours in dogs.

GI distress (vomiting, anorexia) is the most frequently, yet uncommon, reported adverse effect. Although not reported thus far in animals, hypersensitivity reactions, crystalluria, and CNS effects (dizziness, stimulation) could potentially occur. Hematuria, hepatotoxicity may occur. stevens-Johnson Syndrome (blistering, itching, loosening, peeling or redness of skin; diarrhea.

Bubble-like changes in articular cartilage have been noted when the drug was given at 2–5 times recommended doses for 30 days, although clinical signs have only been seen at the 5X dose.

In humans, the FDA categorizes this drug as category C for use during pregnancy (Animal studies have shown an adverse effect on the fetus, but there are no adequate studies in humans; or there are no animal
reproduction studies and no adequate studies in humans.)
Ciprofloxacin is distributed into milk, but oral absorption should be negligible. No adverse effects have been reported in nursing human infants of mothers receiving ciprofloxacin